Adherium Limited (ASX: ADR) Webcast Replay

17th August, 2022

Adherium Limited (ASX: ADR) is a global leader in connected respiratory medical devices, with more than 170,000 sold and 180 patents and designs globally.

As a part of our ‘The Insiders: Meet the CEOs’ series, CEO Rick Legleiter, provides valuable insights to the company, its key markets and industry, and future prospects.

Recorded on 17th August 2022 at 12pm (AEST).

Join the next The Insider: Meet the CEOs webcast

Speak to the Reach Markets team


Rick Legleiter

CEO - Adherium Limited (ASX: ADR)

Adherium provides connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Founded in 2001 and listed on the ASX in 2015, the company’s strategy is focused on the digital health landscape – a US$34 billion market opportunity. Adherium’s Hailie sensor technology and cloud-based data platform provides real-time feedback on patients’ use of inhaled medication, enabling optimal management of difficult-to-treat and severe asthma and Chronic Obstructive Pulmonary Disease (COPD), and reducing healthcare costs. In 2021, Adherium was awarded a supply contract with AstraZeneca for a bespoke version of its Hailie sensor and software solution for its US study.

latest other webcasts

Felix Gold (ASX: FXG) Webcast Replay

Far East Gold (ASX: FEG) Webcast Replay

Prescient Therapeutics (ASX: PTX) Webcast Replay

Speak to the Reach Markets team

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.